Tackling Salami Slicing and Indication Stacking in Orphan Drug Innovation Incentives
Are the incentive mechanisms for orphan drug development working as they should?

Are the incentive mechanisms for orphan drug development working as they should?

Before we can consider ways to address excessive pricing for orphan drugs, we must first diagnose the underlying problem.

What are the implications of a court requiring a doctor to administer a drug they do not believe is medically indicated?

Topics range from issues related to FDA’s approval of aducanumab, to an analysis of the communication of survival data in cancer drug labels.

Activists in the access-to-medicines movement have mobilized to combat the threat of vaccine/therapeutic apartheid during the COVID-19 pandemic.

What are the most pressing priorities for developing new drugs for rare diseases, and how can legal research help meet these needs?

To combat the opioid epidemic, we have to understand how regulators failed to protect the public health as the market for prescription opioids grew.

The pandemic finally shifted the reproductive justice movement’s focus to abortion access, rather than abortion rights.

Because of differences in how they were tested in clinical trials, it is difficult to make apples-to-apples comparisons for COVID-19 vaccines.
